HTL to Invest in Production Facility for Injectable Grade Sodium Hyaluronate
The new Javené, France-based facility is expected to increase the company’s production capacity of injectable grade sodium hyaluronate obtained by fermentation by 2.5 times.
HTL, a hyaluronic acid and biopolymer solutions supplier based in France, announced it will invest in a production facility for injectable grade sodium hyaluronate production. Financial details of the investment were not disclosed.
The new Javené, France-based facility is expected to increase the company’s production capacity of injectable grade sodium hyaluronate obtained by fermentation by 2.5 times by 2021, the company said in an Oct. 30, 2019 press release. It will also boost the global marketing of the company’s medical applications and biopolymer-based innovation.
“This new, unprecedented capacity investment demonstrates the long-term commitment of HTL and its shareholders to anticipate and fulfill the growing needs of its customers worldwide,” said Yvon Bastard, CEO of HTL, in the press release.
HTL will be exhibiting at CPhI Worldwide from Nov. 5–7, 2019 at stand 4.2G13.
Source: HTL
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
